Mohamad M. Kronfol

Mohamad M. Kronfol

Auto-generated profile, based on publicly available information

Mohamad M. Kronfol

Office of Clinical Pharmacology (OCP) OTS | CDER | FDA, White Oak Campus Silver Spring MD USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2017 in Expert Review of Precision Medicine and Drug Development
Verified
Journal Article
Closed access
MKMohamad M. Kronfol
Mohamad M. Kronfol
MDMikhail G. Dozmorov
Mikhail G. Dozmorov
RHRong Huang
Rong Huang
PSPatricia W. Slattum
Patricia W. Slattum
JMJoseph L. McClay
Joseph L. McClay
Introduction: Epigenetics is the study of reversible modifications to chromatin and their extensive and profound effects on gene regulation. To date, the role of epigenetics in personalized medicine has been under-explored. Therefore, this review aims to highlight the vast potential that epigenetics holds. Areas covered: We first review the cell-specific nature of epigenetic states and how these can vary with developmental stage and in response to environmental factors. We then summarize epigenetic biomarkers of disease, with a focus on diagnostic tests, followed by a detailed description of current and pipeline drugs with epigenetic modes of action. Finally, we discuss epigenetic biomarkers of drug response. Expert commentary: Epigenetic variation can yield information on cellular states and developmental histories in ways that genotype information cannot. Furthermore, in contrast to fixed genome sequence, epigenetic patterns are plastic, so correcting aberrant, disease-causing epigenetic marks holds considerable therapeutic promise. While just six epigenetic drugs are currently approved for use in the United States, a larger number is being developed. However, a drawback to current therapeutics is their non-specific effects. Development of locus-specific epigenetic modifiers, used in conjunction with epigenetic biomarkers of response, will enable truly precision interventions.

14 June 2018 in Human Molecular Genetics
Verified
Journal Article
Closed access
HXHanzhang Xia
Hanzhang Xia
FJFay M Jahr
Fay M Jahr
NKNak-Kyeong Kim
Nak-Kyeong Kim
LXLinying Xie
Linying Xie
ASAndrey A Shabalin
Andrey A Shabalin
JMJoseph L McClay
Joseph L McClay
The transcription factor 4 (TCF4) locus is a robust association finding with schizophrenia (SCZ), but little is known about the genes regulated by the encoded transcription factor. Therefore, we conducted chromatin immunoprecipitation sequencing (ChIP-seq) of TCF4 in neural-derived (SH-SY5Y) cells to identify genome-wide TCF4 binding sites, followed by data integration with SCZ association findings. We identified 11 322 TCF4 binding sites overlapping in two ChIP-seq experiments. These sites are significantly enriched for the TCF4 Ebox binding motif (>85% having ≥1 Ebox) and implicate a gene set enriched for genes downregulated in TCF4 small-interfering RNA (siRNA) knockdown experiments, indicating the validity of our findings. The TCF4 gene set was also enriched among (1) gene ontology categories such as axon/neuronal development, (2) genes preferentially expressed in brain, in particular pyramidal neurons of the somatosensory cortex and (3) genes downregulated in postmortem brain tissue from SCZ patients (odds ratio, OR = 2.8, permutation P < 4x10-5). Considering genomic alignments, TCF4 binding sites significantly overlapped those for neural DNA-binding proteins such as FOXP2 and the SCZ-associated EP300. TCF4 binding sites were modestly enriched among SCZ risk loci from the Psychiatric Genomic Consortium (OR = 1.56, P = 0.03). In total, 130 TCF4 binding sites occurred in 39 of the 108 regions published in 2014. Thirteen genes within the 108 loci had both a TCF4 binding site ±10kb and were differentially expressed in siRNA knockdown experiments of TCF4, suggesting direct TCF4 regulation. These findings confirm TCF4 as an important regulator of neural genes and point toward functional interactions with potential relevance for SCZ.

27 March 2020 in GeroScience
Verified
Journal Article
Closed access
PDF file
MKMohamad M. Kronfol
Mohamad M. Kronfol
FJFay M. Jahr
Fay M. Jahr
MDMikhail G. Dozmorov
Mikhail G. Dozmorov
PPPalak S. Phansalkar
Palak S. Phansalkar
LXLin Y. Xie
Lin Y. Xie
JMJoseph L. McClay
Joseph L. McClay

1 September 2020 in NeuroToxicology
Verified
Journal Article
Open access
ARAna C.R. Ribeiro
Ana C.R. Ribeiro
JZJackie Zhu
Jackie Zhu
MKMohamad M. Kronfol
Mohamad M. Kronfol
FJFay M. Jahr
Fay M. Jahr
RYRabha M. Younis
Rabha M. Younis
LDLaxmikant Deshpande
Laxmikant Deshpande
Exposure to organophosphates (OP) during the First Gulf War is among one of the factors for Gulf War Illness (GWI) development in veterans and it has been challenging to treat GWI symptoms with existing therapies. Ketamine produces a rapid-onset and sustained antidepressant response, but there is no evidence whether ketamine treatment is effective for GWI depression. Repeated, low-dose exposure to diisopropyl fluorophosphate (DFP) mimic Gulf War related OP exposures and produces a chronic depressive state in rats. In this study, DFP-exposed rats treated with ketamine (10 mg/kg, i.p.) exhibited antidepressant-like effect on the Forced Swim Test at 1-h. This effect persisted at 24-h post ketamine, a time-point by which it is eliminated from the brain suggesting involvement of mechanisms that affect long-term synaptic plasticity. Western blot analysis showed significantly lower Brain-Derived Neurotrophic Factor (BDNF) levels in DFP rat brains. Ketamine produced a nonsignificant increase in BDNF expression at 1-h but produced a larger, significant (2.2-fold) increase at 24-h in DFP rats. We previously reported chronic hippocampal calcium elevations ([Ca2+]i) in DFP rats. Ketamine-treated DFP rats exhibited significantly lower [Ca2+]i at 1-h but not at 24-h. Interestingly, treatment with ANA-12, a TrkB-BDNF receptor antagonist, in DFP rats blunted ketamine's antidepressant-like effect at 24-h but not at 1-h. These experiments suggest that in a rat model of DFP-induced depression, inhibition of the NMDAR-Ca2+ contributes to the rapid-onset antidepressant effects of ketamine while the antidepressant actions that persisted at 24-h post ketamine administration involve upregulation of BDNF signaling.

16 August 2024 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
BEBrianna Eales
Brianna Eales
NHNada A. Helal
Nada A. Helal
OVOlivia Vattelana
Olivia Vattelana
MKMohamad M. Kronfol
Mohamad M. Kronfol
EFElimika Pfuma Fletcher
Elimika Pfuma Fletcher
MNMohamed Ismail Nounou
Mohamed Ismail Nounou

1 January 2019
Verified
Book Chapter
Closed access
MKMohamad M. Kronfol
Mohamad M. Kronfol
JMJoseph L. McClay
Joseph L. McClay